- Active not recruitingPHASE3
Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Omalizumab as Active Control, in Adult CSU Patients, Followed by an Open-label 52-week Optional Extension.
This study looks at a new medicine called remibrutinib for chronic spontaneous urticaria (CSU), comparing it to a dummy treatment (placebo) and another existing medicine, omalizumab. It aims to see if remibrutinib is safe and helps reduce hives and itching in adults whose CSU isn't well controlled by usual allergy medicines.
For: Chronic Spontaneous UrticariaArgentina · Brazil · Bulgaria - Ongoing, recruitingTherapeutic use (Phase IV)
Predictive factors and magnitude of response to omalizumab and mepolizumab in allergic and eosinophilic severe asthma: PREDICTUMAB, an open-label, controlled, randomized multinational pragmatic trial.
This study compares two existing asthma medications, omalizumab and mepolizumab, for people with severe allergic or eosinophilic asthma. It aims to see which treatment better prevents severe asthma attacks and how well each drug works overall in different groups of people.
For: Severe allergic and eosinophilic asthmaBelgium · France